溃疡性结肠炎
医学
胃肠病学
纳米载体
药品
炎症性肠病
结肠炎
内科学
腹泻
不利影响
疾病
药理学
作者
Amandeep Singh,Kirandeep Kaur,Veerpal Kaur,Gurmeet Singh,Uttam Kumar Mandal,Neeraj Mishra,Raj Kumar Narnag
出处
期刊:Journal of Drug Delivery and Therapeutics
[Society of Pharmaceutical Tecnocrats]
日期:2019-12-15
卷期号:9 (6-s): 216-228
被引量:7
标识
DOI:10.22270/jddt.v9i6-s.3727
摘要
Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form the entire colon is involved. Ulcerative colitis is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressant are used for therapy of ulcerative colitis. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2 and 24.3 per 100,000 people-years. The main challenges in the management of the diseaseare drug-related side-effects and local targeting. To overcome these challenges probiotics and micro and Nano particulate system auspicious approaches to overcome drug-related adverse side effect and local targeting. Upon ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also now days explored for their use in ulcerative colitis. Micro and Nano particulate drug delivery system have been achieving huge importance for targeting of the drug to colon locally at a controlled and sustained rate. The main objective of this article is to explore probiotics and micro and nano particulate approaches for the suitable targeting and overcome the drug-associated side effect.
Keywords: Inflammatory chronic disease, probiotics, micro and Nano particulate.
科研通智能强力驱动
Strongly Powered by AbleSci AI